<DOC>
	<DOC>NCT02100813</DOC>
	<brief_summary>To identify the Maximum Tolerated Dose levels of LEO 43204 after once daily treatment for two consecutive days and to evaluate efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle</brief_summary>
	<brief_title>Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the full balding scalp. Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the full balding scalp Location of the treatment area within 5 cm of an incompletely healed wound within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) Prior treatment with ingenol mebutate gel on the treatment area Lesions in the treatment areas that have atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous horns) and/or recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>